[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-355911-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-355911-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","identification-of-g4-regulated-immune-related-drug-targets-for-prostate-cancer-based-on-g4-screen-and-machine-learning","Identiﬁcation of G4-regulated immune-related drug targets for prostate cancer based on G4 screen and machine learning","","G-quadruplex (G4) structures function as epigenetic regulators and potential therapeutic targets, yet their contribution to prostate cancer immune microenvironments remains unclear. This study maps genome-wide G4 landscapes in prostate cancer cells using BG4 ChIP-seq, then integrates G4-associated genes with immune pathway enrichment and machine-learning feature selection. Hub identification highlights IKBKB as a key driver associated with advanced disease and poor prognosis. Functional assays and computational druggability pipelines support G4 stabilization and propose G4 promoter disruption plus AI-designed peptide inhibitors as therapeutic strategies.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/identification-of-g4-regulated-immune-related-drug-targets-for-prostate-cancer-based-on-g4-screen-and-machine-learning/355911/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/identification-of-g4-regulated-immune-related-drug-targets-for-prostate-cancer-based-on-g4-screen-and-machine-learning/355911.png","ImageObject",300,407,{"name":42,"@type":43},"Elsa","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-04","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",9,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main purpose of this study on prostate cancer?","Question",{"text":63,"@type":64},"To identify G4-regulated, immune-related drug targets in prostate cancer by mapping G4 structures and integrating them with immune pathway analysis and machine learning.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"Which hub gene is highlighted as central to prostate cancer progression?",{"text":68,"@type":64},"IKBKB is pinpointed as a key hub gene, linked to advanced stage, poor prognosis, and immune microenvironment remodeling.",{"name":70,"@type":61,"acceptedAnswer":71},"What therapeutic strategies are proposed based on the findings?",{"text":72,"@type":64},"Two strategies are proposed: disrupting G4 at the IKBKB promoter and using AI-designed peptide inhibitors targeting IKBKB, including a CRISPR-dCas9-based approach for G4 disruption.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},355911,1790968641,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},137455077381,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","TYPE Original Research PUBLISHED 10 June 2026  \nDOI 10.3389/fimmu.2026.1806289  \nOPEN ACCESS  \nEDITED BY  \nJosephine Ataa Hinneh,  \nUniversity of California, San Francisco, United States  \nREVIEWED BY  \nMaria Razzaq,  \nSungkyunkwan University, Republic of Korea Changchang Cao,  \nNational Center for Cardiovascular Disease, China  \n*CORRESPONDENCE  \nMinhao Zhang  \n[zmhjj1981@163.com](zmhjj1981@163.com)[ ](zmhjj1981@163.com)ChangBin Yang  \n[xbbyang@fmmu.edu.cn](xbbyang@fmmu.edu.cn)[ ](xbbyang@fmmu.edu.cn)Dongfang Jiang  \n[13912823872@163.com](13912823872@163.com)[ ](13912823872@163.com)Yuanji Shen  \n[115345795@qq.com](115345795@qq.com)[ ](115345795@qq.com)Bing Zheng  \n [ntzb2008@163.com](ntzb2008@163.com)[ ](ntzb2008@163.com)Chuanjun Shu  \n [chuanjunshu@njmu.edu.cn](chuanjunshu@njmu.edu.cn)  \n†These authors have contributed equally to this work  \nRECEIVED 07 February 2026  \nREVISED 11 May 2026  \nACCEPTED 18 May 2026  \nPUBLISHED 10 June 2026  \nCITATION  \nGe L, Hou Y, Huang X, Zhang J, Yao L, Chen S, Mao L, Ning W, Liang H, Shi N, Yang C, Jiang D, Shen Y, Zheng B, Shu Cand Zhang M (2026) Identiﬁcation of G4-regulated immune-related drug targets for prostate cancer based on G4 screen and machine learning.  \nFront. Immunol. 17:1806289 .  \ndoi: 10.3389/fimmu.2026.1806289  \nCOPYRIGHT  \n© 2026 Ge, Hou, Huang, Zhang, Yao, Chen, Mao, Ning, Liang, Shi, Yang, Jiang, Shen, Zheng, Shu and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nIdentiﬁcation of G4-regulated immune-related drug targets for prostate cancer based on G4 screen and machine learning  \nLiu Ge 1,2†, Yue Hou 3†, Xuan Huang 4†, Jiawei Zhang 2†, Lin Yao 5†, Saisai Chen 2, Likai Mao 2, Wei Ning 3, Han Liang 3, Nini Shi 3, ChangBin Yang3*, Dongfang Jiang6*, Yuanji Shen 7*,  \nBing Zheng 8*, Chuanjun Shu 9*† and Minhao Zhang 1*  \n1 Department of Urology, Xishan People’s Hospital of Wuxi City, Wuxi, Jiangsu, China, 2 Department of Urology, Afﬁliated Zhongda Hospital of Southeast University, Nanjing, Jiangsu, China, 3 Military Medical Innovation Center, Fourth Military Medical University, Xi’an, China, 4 Reproductive Medical Center, Jinling Hospital Afﬁliated to Medical School of Nanjing University, Nanjing, Jiangsu, China,  \n5 Department of Oncology, Jinling Hospital Afﬁliated to Medical School of Nanjing University, Nanjing, Jiangsu, China, 6The People’s Hospital of Danyang, Afﬁliated Danyang Hospital of Nantong University, Danyang, Jiangsu, China, 7 Department of Urology, Nanjing Pukou Hospital of Traditional Chinese Medicine (TCM), Nanjing, Jiangsu, China, 8 Department of Urology, Southeast University Afﬁliated Nantong First People’s Hospital, Nantong, Jiangsu, China, 9 Department of Bioinformatics, School of Biomedical Engineering and Informatics, Nanjing Medical University, Nanjing, China  \nBackground: G-quadruplex (G4) structures are important epigenetic regulators and potential therapeutic targets in cancer. However, their role in prostate cancer, particularly in relation to the immune microenvironment, remains poorly understood.  \nMethods: We performed BG4 ChIP-seq to map genome-wide G4 structures in the prostate cancer cell line C4-2 . Bioinformatics analyses integrated G4-associated genes with immune pathway enrichment and machine learning algorithms (LASSO, SVM-RFE, GBM, Naïve Bayes, and GLM) to identify hub genes in prostate cancer progression. Clinical data from GTEx, TCGA, and HPA were analyzed for expression and survival. Functional validation included qPCR, CCK-8, colony formation, and wound-healing assays. Druggability was assessed using DrugnomeAI, and AI-assiste","cbCaifhbwCoXjhTB","https://ap.wps.com/l/cbCaifhbwCoXjhTB","pdf",19770337,17,"English","# Background\n## Methods\n# Results\n## Conclusions","[{\"question\":\"What is the main purpose of this study on prostate cancer?\",\"answer\":\"To identify G4-regulated, immune-related drug targets in prostate cancer by mapping G4 structures and integrating them with immune pathway analysis and machine learning.\"},{\"question\":\"Which hub gene is highlighted as central to prostate cancer progression?\",\"answer\":\"IKBKB is pinpointed as a key hub gene, linked to advanced stage, poor prognosis, and immune microenvironment remodeling.\"},{\"question\":\"What therapeutic strategies are proposed based on the findings?\",\"answer\":\"Two strategies are proposed: disrupting G4 at the IKBKB promoter and using AI-designed peptide inhibitors targeting IKBKB, including a CRISPR-dCas9-based approach for G4 disruption.\"}]","Identiﬁcation of G4-regulated immune-related drug targets for prostate cancer based on G4 screen and machine learning | PDF",1790121689,43,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f5b571d8bf0fe0ce7a4d6ce43923f5be.webp",983,1389,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/f6a5f37d55ebe7e5f59cd28ea5ff0ecd.webp",982,1388,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/325e8511452b8e5bd747ac2fc0254a3b.webp",981,1386,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c2368151c087af0f68c31c8d188d780a.webp",980,1385]